Behavioral Resources and Awareness for Veterans With Episodic Migraine: Impact on Neurological Disability and Quality of Life- Pilot
Part of paid clinical trials in West Haven, Connecticut.
- Sponsor
- Yale University
- Study ID
- NCT07792291
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Episodic Migraine Headache
- Migraine
- Migraine Headache
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cognitive behavioral therapy for migraine (CBTm) — BEHAVIORALA standardized multi-modal behavioral treatment protocol typically delivered by psychologists via six sessions to help people better manage their migraine through behavior changes, warning sign identification and acute treatment optimization, medication adherence, and restructuring unhelpful thoughts about migraine and stress.
- MEintervention — BEHAVIORALA digital intervention delivered via six 15-minute remote education sessions with a study research assistant from the VA Connecticut coordination center.
Study Details
The current study will evaluate effectiveness of cognitive behavioral therapy for migraine compared to migraine education (ME) to improve migraine-related quality of life in the real-world setting of the Veterans Health Administration (VHA).
Key Dates
- First listed
- Aug 28, 2026
- Start date
- Oct 31, 2026
- Status verified
- Aug 2026
- Primary completion
- Oct 31, 2027
- Completion
- Oct 31, 2027
Study Design
- Enrollment
- 24 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Cognitive behavioral therapy for migraine (CBTm)Participants to receive 6 sessions of CBTm
- Experimental: Migraine education intervention (MEintervention)Participants to receive 6 sessions of a remotely delivered interactive MEintervention
Primary Outcome Measure
Retention Rate [ Time Frame: From randomization to week 12 ]
Central Contacts
- Sarah McGlone, MS203-932-5711
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| VA Connecticut Healthcare System | West Haven | Connecticut | 06516 | - |
| VA South Texas Healthcare System | San Antonio | Texas | 78224 | - |
Find similar trials in West Haven, CT
Nationwide
By condition
By specialty
Related Studies
- Pain Biomarker StudyPHASE1 · Enrolling By Invitation · The University of Texas Health Science Center, Houston · Houston, Texas
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)PHASE3 · Recruiting · AbbVie · Huntsville, Alabama
- Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)PHASE3 · Enrolling By Invitation · AbbVie · Huntsville, Alabama
- Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric SubjectsPHASE3 · Recruiting · Pfizer · Hawthorne, California